Physician profile
Maria E Goleba
NPI 1306834429
$6,721.12
in general payments reported to CMS, 2019-2025
43 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $346 · 2021: $149 · 2022: $1,876 · 2023: $1,894 · 2024: $1,302 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,235 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $180 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180.00 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.37 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,013.26 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $518.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $395.79 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $371.96 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.34 | 2019-2024 | Jardiance, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $188.02 | 2019-2023 | |
| Lilly USA, LLC | $172.66 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $154.51 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $142.54 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $132.61 | 2022-2024 | Rexulti, Abilify Mycite |
| Glaxosmithkline, LLC. | $124.62 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $110.30 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $98.76 | 2019-2022 | |
| Exact Sciences Corporation | $98.07 | 2023-2024 | Cologuard Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Goleba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.